TROPION-PanTumor03 trial: what clinicians have said so far
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05489211 ↗
- Recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on TROPION-PanTumor03 (datopotamab deruxtecan; datopotamab deruxtecan plus capecitabine; datopotamab deruxtecan plus 5-fluorouracil in advanced/metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPION-PanTumor03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X | |
| 2 YouTube videos | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Urothelial Cancer; Biliary Tract Cancer
- Interventions
- Datopotamab deruxtecan (Dato-DXd); Capecitabine; 5-Fluorouracil; Volrustomig; Carboplatin; Bevacizumab; Rilvegostomig; Prednisone/ prednisolone; Cisplatin
- Arms
- Substudy-1A · Experimental
- Substudy-2A · Experimental
- Substudy-2B · Experimental
- Substudy-3A · Experimental
- Substudy-3C · Experimental
- Substudy-4A · Experimental
- Substudy-4C · Experimental
- Substudy-5A · Experimental
- Substudy-6A · Experimental
- Substudy-6B · Experimental
- Substudy-6C · Experimental
- Substudy-6D · Experimental
- Substudy-6E · Experimental
- Substudy-7A · Experimental
- Enrollment
- 454 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- The number of subjects with adverse events/serious adverse events
- PSA50 response (Substudy 3 only)
- Progression free survival (PFS) response (Substudy 4C only)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Sep 6, 2022
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05489211 · updated Sep 23, 2026